<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130953">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678677</url>
  </required_header>
  <id_info>
    <org_study_id>116647</org_study_id>
    <nct_id>NCT01678677</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers</brief_title>
  <official_title>An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Belgium: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8
      different formulations of investigational NTHI vaccine in current and former smokers, 50-70
      years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Protocol Posting has been updated following Protocol Amendment 1, dated 10 October
      2012, leading to a change in an inclusion criterion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Occurrence of each solicited local and general adverse event (AE), in all subjects, in all groups.</measure>
    <time_frame>During a 7-day follow-up period (from day 0 to day 6) after each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any unsolicited AE, in all subjects, in all groups.</measure>
    <time_frame>During a 30-day follow-up period (from day 0 to day 29) after each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all groups.</measure>
    <time_frame>Prior to each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all groups.</measure>
    <time_frame>7 days after each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of  haematological and biochemical laboratory abnormalities, in all subjects, in all groups.</measure>
    <time_frame>At study conclusion (Day 420).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any serious adverse event (SAE), in all subjects, in all groups.</measure>
    <time_frame>From first vaccination (Day 0) to study conclusion (Day 420).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any potential immune-mediated disease (pIMD) in all subjects, in all groups.</measure>
    <time_frame>From first vaccination (Day 0) to study conclusion (Day 420).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response to the components of the NTHi vaccine formulations, in all subjects, in all groups, in terms of antibody concentrations.</measure>
    <time_frame>Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune (CMI) responses to components of the NTHi vaccine formulations, in a sub-cohort of subjects, in all groups.</measure>
    <time_frame>Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 1 of NTHi vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 2 of NTHi vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 3 of NTHi vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 4 of NTHi vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838500A (formulation 1)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838501A (formulation 2)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838502A (formulation 3)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838503A (formulation 4)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838504A (formulation 5)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838505A (formulation 6)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838508A (formulation 7)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTHI vaccine GSK2838509A (formulation 8)</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group Placebo 1</arm_group_label>
    <arm_group_label>Group Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol.

          -  A male or female between, and including, 50 and 70 years of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the subject.

          -  Subjects without medical history, clinical finding or laboratory finding which in the
             opinion of the investigator could pose a safety concern or interfere with the
             protocol.

          -  Current or former smokers.

          -  A smoking history of at least 10 pack-years.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol in the period starting 30 days before the first dose and ending 30 days
             after the last dose of vaccine, with the exception of any influenza vaccine which may
             be administered ≥ 15 days preceding or following any study vaccine dose.

          -  Previous vaccination with any vaccine containing NTHi-antigens.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose. Topical steroids are allowed.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of or current autoimmune disease.

          -  Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) &lt; 80% of predicted
             normal value.

          -  Diagnosed with a respiratory disorder. Please note that subjects with mild pulmonary
             obstruction can be enrolled.

          -  Laboratory evidence of clinically significant haematological abnormalities at
             Screening.

          -  Acute disease and/or fever at the time of enrolment.

          -  Current alcoholism and/or drug abuse.

          -  Has significant disease, in the opinion of the investigator, likely to interfere with
             the study and/or likely to cause death within the study duration.

          -  History of or current condition preventing intramuscular injection as bleeding or
             coagulation disorder.

          -  Has contraindication for spirometry testing.

          -  Malignancies within previous 5 years and lymphoproliferative disorders.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Any other condition that the investigator judges may interfere with study findings.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-typeable Haemophilus influenzae</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>reactogenicity</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
